6712 Stock Overview
Engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Ever Supreme Bio Technology Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$173.00 |
| 52 Week High | NT$215.00 |
| 52 Week Low | NT$166.00 |
| Beta | 0.32 |
| 1 Month Change | -1.42% |
| 3 Month Change | -5.21% |
| 1 Year Change | -1.14% |
| 3 Year Change | 4.16% |
| 5 Year Change | 40.80% |
| Change since IPO | 152.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6712 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.3% | -2.6% | -2.1% |
| 1Y | -1.1% | -0.8% | 25.6% |
Return vs Industry: 6712 matched the TW Biotechs industry which returned -0.8% over the past year.
Return vs Market: 6712 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 6712 volatility | |
|---|---|
| 6712 Average Weekly Movement | 1.8% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6712 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6712's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.ever-supreme.com.tw |
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan.
Ever Supreme Bio Technology Co., Ltd Fundamentals Summary
| 6712 fundamental statistics | |
|---|---|
| Market cap | NT$13.96b |
| Earnings (TTM) | NT$254.33m |
| Revenue (TTM) | NT$844.86m |
54.9x
P/E Ratio16.5x
P/S RatioIs 6712 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6712 income statement (TTM) | |
|---|---|
| Revenue | NT$844.86m |
| Cost of Revenue | NT$253.38m |
| Gross Profit | NT$591.48m |
| Other Expenses | NT$337.15m |
| Earnings | NT$254.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.15 |
| Gross Margin | 70.01% |
| Net Profit Margin | 30.10% |
| Debt/Equity Ratio | 0% |
How did 6712 perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield173%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ever Supreme Bio Technology Co., Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Xiaowei Huang | Masterlink Securities Corp. |
| Jane Jiang | Yuanta Research |